U.S. Space Startup Flies High--In Both English And Russian

When the space shuttle Columbia touched down in late 1983, payload specialist Byron K. Lichtenberg emerged from the Spacelab-1 mission both triumphant and troubled. The experiments—on everything from astronomy to protein crystal growth studies—had gone exceedingly well, and the National Aeronautics and Space Administration wanted him to fly again. There was, however, a slight problem: Lichtenberg, a biomedical engineer, was about to become unemployed. For the five years leading u

Written byBruce Fellman
| 4 min read

Register for free to listen to this article
Listen with Speechify
0:00
4:00
Share

When the space shuttle Columbia touched down in late 1983, payload specialist Byron K. Lichtenberg emerged from the Spacelab-1 mission both triumphant and troubled. The experiments—on everything from astronomy to protein crystal growth studies—had gone exceedingly well, and the National Aeronautics and Space Administration wanted him to fly again.

There was, however, a slight problem: Lichtenberg, a biomedical engineer, was about to become unemployed.

For the five years leading up to Spacelab, the energetic scientist had worked at the Massachusetts Institute of Technology’s Manned Vehicle Laboratory. Much of his research involved an experiment on space motion-sickness that he and MIT graduate student Anthony P. Arrott, who manned a Mission Control console during the trip, had prepared for Lichtenberg's first shuttle flight, But because MIT had no experiments scheduled, for the next flight, Lichtenberg,s job at the Cambridge, Mass., universiy was to end with that Spacelab mission.

What to do? Almost ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies